Author

I.‐M. Wang

Observed names: I-M. Wang, I.-M. Wang

Institution: Pfizer (United States)

Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Pfizer (United States)

ORCID: 0000-0001-9414-0394

Observed ORCID: 0000-0001-9414-0394

OpenAlex ID: A5113181925

A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations

2024 · J. Rodon, E. Rodriguez, et al. · ESMO Open · 57

Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study

2026 · A.T. Shaw, B.J. Solomon, et al. · Annals of Oncology · 21

Gene expression analysis in serial liver fine needle aspirates

2014 · S. Lejnine, M. J. Marton, et al. · Journal of Viral Hepatitis · 11

First-in-human phase I study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of PF-07209960 in patients with advanced or metastatic solid tumors

2025 · A. Naing, M. McKean, et al. · ESMO Open · 7

P2.238: Early On-Treatment Prediction of Long-Term PFS Using a Joint AI-Imaging and ctDNA Model in the CROWN Study

2026 · H. Zhang, I.-M. Wang, et al. · Journal of Thoracic Oncology

1981P Longitudinal methylation- vs genomic-based circulating tumor DNA molecular response analysis in patients with ALK+ advanced non-small cell lung cancer treated with lorlatinib in the CROWN study

2025 · T.S.K. Mok, I-M. Wang, et al. · Annals of Oncology

Works count: 6

Citation count: 96

H-index: 4

I10-index: 3